Osimertinib, a third-generation epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI), is widely used to treat EGFR-mutated non-small cell lung cancer (NSCLC) because of its high efficacy and favourable safety profile. However, rare but serious... ...

请注册登录后继续浏览